# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 167


For regulation 211 (amendment of regulation 279 (products without a marketing authorisation)) substitute—
“211. For regulation 279 substitute—
“279. (1) A person may not publish an advertisement in Great Britain for a medicinal product unless one of the following is in force for the product—
(a) a UKMA(GB) or UKMA(UK);
(b) a COR(GB) or COR(UK); or
(c) a THR(GB) or THR(UK).
(2) A person may not publish an advertisement in Northern Ireland for a medicinal product unless one of the following is in force for the product—
(a) a UKMA(NI) or UKMA(UK);
(b) a COR(NI) or COR(UK);
(c) a THR(NI) or THR(UK);
(d) an EU marketing authorisation; or
(e) an Article 126a authorisation.
(3) A person may not publish an advertisement in the whole United Kingdom for a medicinal product unless, in relation to that product—
(a) one of the authorisations or registrations specified in paragraph (1) is in force in Great Britain; and
(b) one of the authorisations or registrations specified in paragraph (2) is in force in Northern Ireland.”.”.

---
Source: https://www.legislation.gov.uk/ukdsi/2020/9780348213980/schedule/2/paragraph/167 (the official version)
Page: https://openlegislation.uk/draft-human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-167
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.